Characterization of zolbetuximab in pancreatic cancer models
Author:
Affiliation:
1. Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany
2. Astellas Pharma, Inc., Tokyo, Japan
3. TRON – Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
Funder
Ganymed Pharmaceuticals GmbH (formerly Ganymed Pharmaceuticals AG), a wholly owned subsidiary of Astellas Pharma, Inc
Publisher
Informa UK Limited
Subject
Oncology,Immunology,Immunology and Allergy
Link
https://tandfonline.com/doi/pdf/10.1080/2162402X.2018.1523096
Reference23 articles.
1. Antibody therapy of cancer
2. Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
3. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
4. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
5. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets;Journal of Pharmacological Sciences;2024-11
2. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence;Translational Oncology;2024-09
3. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors;Cell Reports Medicine;2024-09
4. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials;ESMO Open;2024-08
5. Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the 99mTc-Labeled Nanobody (PHG102) Radiotracer;ACS Pharmacology & Translational Science;2024-07-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3